The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3‐Glucuronide Metabolites
Abstract
SUMMARY: 1. Morphine is recommended by the World Health Organization as the drug of choice for the management of moderate to severe cancer pain. 2. Education of health professionals in the past decade has resulted in a large increase in the prescribing of opioids, such as morphine, and in the magnitude of the doses administered, resulting in an improvement in the quality of pain relief available for many cancer patients. 3. However, the reported incidence of neuroexcitatory side effects (allodynia, myoclonus, seizures) in patients administered large doses of systemic morphine or its structural analogue, hydromorphone (HMOR), has also increased. 4. Clinically, increasing the magnitude of the morphine or HMOR dose administered to patients already exhibiting neuroexcitatory opioid related side effects, results in an exacerbation rather than an attenuation of the excitatory behaviours. 5. In contrast, cessation of the opioid or rotation to a structurally dissimilar opioid (e.g. from morphine/HMOR to methadone or fentanyl), usually results in a restoration of analgesia and resolution of the neuroexcitatory opioid side effects over a period of hours to days. 6. To explain the clinical success of ‘opioid rotation’, it is essential to understand the in vivo metabolic fate of morphine and HMOR. 7. Following systemic administration, morphine and HMOR are metabolized primarily to the corresponding 3‐glucuronide metabolites, morphine‐3‐glucuronide (M3G) and hydromorphone‐3‐glucuronide (H3G), which are not only devoid of analgesic activity but evoke a range of dose‐dependent excitatory behaviours, including allodynia, myoclonus and seizures, following intracerebroventricular (i.c.v.) administration to rats. 8. Several studies have shown that, following chronic oral or subcutaneous morphine administration to patients with cancer pain, the cerebrospinal fluid (CSF) concentrations of M3G exceed those of morphine and morphine‐6‐glucuronide (analgesically active morphine metabolite) by approximately two‐ and five‐fold, respectively. 9. These findings suggest that when the M3G concentration (or H3G by analogy) in the CSF exceeds the neuroexcitatory threshold, excitatory behaviours will be evoked in patients. 10. Thus, rotation of the opioid from morphine/HMOR to a structurally dissimilar opioid, such as methadone or fentanyl, will allow clearance of M3G/H3G from the patient central nervous system over hours to days, thereby producing a time‐dependent resolution of the neuroexcitatory behaviours while maintaining analgesia with methadone or fentanyl.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morphine and Enkephalin: Analgesic and Epileptic Properties
Urca, G., Frenk, H., Liebeskind, J. C., & Taylor, A. N. (1977) · Science · doi:10.1126/science.867056 · Cited by 357
Ebert, B., Andersen, S., & Krogsgaard-Larsen, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11364-3 · Cited by 255
Yaksh, T. L., Harty, G. J., & Onofrio, B. M. (1986) · Anesthesiology · doi:10.1097/00000542-198605000-00008 · Cited by 253
Milne, R. W., Nation, R. L., & Somogyi, A. A. (1996) · Drug Metabolism Reviews · doi:10.3109/03602539608994011 · Cited by 215
Sjøgren, P., Jensen, N.-H., & Jensen, T. S. (1994) · Pain · doi:10.1016/0304-3959(94)90084-1 · Cited by 180
Intrathecal high dose morphine produces hyperalgesia in the rat
Woolf, C. J. (1981) · Brain Research · doi:10.1016/0006-8993(81)90176-1 · Cited by 169
LaBella, F. S., Pinsky, C., & Havlicek, V. (1979) · Brain Research · doi:10.1016/0006-8993(79)90849-7 · Cited by 151
Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine
Sjøgren, P., Jonsson, T., Jensen, N., Drenck, N.-E., & Jensen, T. S. (1993) · Pain · doi:10.1016/0304-3959(93)90188-u · Cited by 143
Bartlett, S. E., Cramond, T., & Smith, M. T. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00552-4 · Cited by 105
Self-citation
Cited by
A Comprehensive Review of Opioid-Induced Hyperalgesia
Lee, M. O. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/145 · Cited by 1,118
Smith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Clinical Pharmacology of Opioids for Pain
Inturrisi, C. E. (2002) · The Clinical Journal of Pain · doi:10.1097/00002508-200207001-00002 · Cited by 571
Opioids in renal failure and dialysis patients
Dean, M. (2004) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.02.021 · Cited by 501
Metadata
- Authors
- Smith, M.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2000-07-17
- Volume
- 27
- Issue
- 7
- Pages
- 524-528
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W1982176799
- Cited by
- 293
- References
- 19
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3‐Glucuronide Metabolites. https://app.cochat.ai/papers/10.1046/j.1440-1681.2000.03290.x
- The paper
- Smith, M. (2000). Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3‐Glucuronide Metabolites. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1046/j.1440-1681.2000.03290.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.